Fisher & Paykel Healthcare logo

FPH - Fisher & Paykel Healthcare News Story

NZD33.3 -0.5  -1.5%

Last Trade - 5:59am

Sector
Healthcare
Size
Large Cap
Market Cap £10.03bn
Enterprise Value £10.01bn
Revenue £825.8m
Position in Universe 31st / 1911

UPDATE 1-Fisher & Paykel says UK court rules rival Resmed's patent is invalid

Sun 12th November, 2017 10:11pm
* UK court rules Resmed's patent for mask invalid - F&P 
Healthcare 
    * Allows F&P Healthcare to sell similar masks in UK 
    * Legal proceedings still underway in Germany and U.S. 
 
 (Adds context on wider legal proceedings, market reaction) 
    WELLINGTON, Nov 13 (Reuters) - New Zealand's Fisher & Paykel 
Healthcare  FPH.NZ  said on Monday that it could continue to 
sell its sleep apnea masks in Britain as a UK court had ruled 
that rival Resmed Inc's  RMD.N  patent was invalid.  
    Fisher & Paykel filed the case against California-based 
Resmed in Britain's High Court in 2016, and has similar legal 
proceedings underway in Germany, after Resmed had said the New 
Zealand company's masks violated Resmed patents. 
    "This result confirms that UK patients can continue to 
purchase and enjoy the benefits of our high-performance masks," 
Fisher & Paykel said in a statement in which it announced the UK 
court ruling. 
    Resmed said in a statement that it was "disappointed" in the 
court's decision and was considering an appeal. It added that  
the ruling had no impact on its court proceedings in other 
countries.  
    The U.S. company has launched legal action against Fisher & 
Paykel in Germany and the United States. 
    It is pursuing court proceedings in a U.S. District Court, 
but dropped a complaint against Fisher & Paykel to the U.S. 
International Trade Commission in May. 
    "We are confident that when the courts in those countries 
apply their different evidentiary rules and validity procedures, 
we will prevail," Resmed said in the statement. 
    In September, a German court suspended the American firm's 
intellectual property proceedings against Fisher & Paykel while 
the two waited for the outcome of a European Patent Office 
decision over Resmed's patents.  urn:newsml:reuters.com:*:nL4N1M95V4 
    Fisher & Paykel shares were largely unchanged on Monday, 
edging down 0.8 percent after the stock market opened to 
NZ$13.20 ($9.14), just below a record high of $13.55 hit last 
week. 
   
($1 = 1.4447 New Zealand dollars) 
 
 (Reporting by Charlotte Greenfield; Editing by Susan Fenton) 
 ((charlotte.greenfield@thomsonreuters.com; +64212437821; 
Reuters Messaging: 
charlotte.greenfield.thomsonreuters.com@reuters.net)) 
 
Keywords: RESMED F&PHEALTHCARE/LAWSUIT
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.